CGEN Positive Sentiment Score: 75/100
Compugen to Present at SITC 2025
Monday, October 6, 2025 1 min read
Key Takeaway: Compugen Ltd. announced that it will present a trial in progress for its anti-IL18BP antibody, COM503, at the upcoming SITC 2025 conference. The presentation will take place on November 7, 2025, and will be led by Dr. Manish Sharma. This trial focuses on participants with advanced solid malignancies, showcasing Compugen's commitment to cancer immunotherapy development.
Full Press Release Details
HOLON, Israel,Oct. 6, 2025/PRNewswire/ --Compugen Ltd.(Nasdaq:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powered by AI/ML today announced, that a trial in progress of the first in human clinical trial to assess the anti-IL18BP antibody, COM503 (GS-0321) in participants with advanced solid malignancies will be presented at the 40thAnnual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 7-9, 2025, in National Harbor, Maryland.
Poster presentation details:Abstract Title:A First in human clinical trial to assess the anti-IL18BP antibody, COM503 (GS-0321) in Participants with Advanced Solid MalignanciesAbstract number:589Presenter:Dr. Manish Sharma, MD, Co-Director of Clinical Research, START Midwest, Grand RapidsDate: Friday, November 7, 2025
About CompugenCompugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development, is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Company contact:Yvonne Naughton, Ph.D.Vice President, Head of Investor Relations and Corporate CommunicationsEmail:[email protected]Tel: +1 (628) 241-0071